We are live on ! Find out more
GCP

GSA Capital Partners Portfolio holdings

AUM $1.59B
1-Year Est. Return 39.81%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$1.32B
AUM Growth
-$106M
Cap. Flow
-$178M
Cap. Flow %
-13.42%
Top 10 Hldgs %
3.73%
Holding
2,115
New
538
Increased
461
Reduced
531
Closed
578

Top Sells

Rank Stock Value
1
FISV
Fiserv Inc
FISV
+$5.58M
2
DVN icon
Devon Energy
DVN
+$4.57M
3
STT icon
State Street
STT
+$4.35M
4
IEX icon
IDEX
IEX
+$4.05M
5
SN icon
SharkNinja
SN
+$3.73M

Sector Composition

Rank Sector Weight
1 Technology 16.98%
2 Healthcare 13.84%
3 Consumer Discretionary 13.31%
4 Financials 12.89%
5 Industrials 11.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALXO icon
1501
ALX Oncology
ALXO
$290M
$88K 0.01%
+48,204
New +$179K
CCCC icon
1502
C4 Therapeutics
CCCC
$412M
$88K 0.01%
15,446
-7,822
-34% -$47.1K
LCTX icon
1503
Lineage Cell Therapeutics
LCTX
$278M
$84K 0.01%
+93,032
New +$86.2K
CXDO icon
1504
Crexendo
CXDO
$222M
$82K 0.01%
17,598
+5,139
+41% +$22.3K
JRVR icon
1505
James River Group Holdings
JRVR
$217M
$81K 0.01%
12,928
-33,592
-72% -$247K
XERS icon
1506
Xeris Biopharma Holdings
XERS
$1.45B
$78K 0.01%
27,350
-578,313
-95% -$1.49M
BKD icon
1507
Brookdale Senior Living
BKD
$3.4B
$76K 0.01%
11,234
-266,018
-96% -$1.9M
HOOK
1508
DELISTED
HOOKIPA Pharma
HOOK
$71K 0.01%
16,609
+4,645
+39% +$24.5K
BRBS icon
1509
Blue Ridge Bankshares
BRBS
$332M
$68K 0.01%
+24,353
New +$66.5K
GOSS icon
1510
Gossamer Bio
GOSS
$87M
$67K 0.01%
+67,546
New +$65K
IPM
1511
Intelligent Protection Management Corp
IPM
$24.1M
$65K ﹤0.01%
+20,000
New +$77.2K
TSVT
1512
DELISTED
2seventy bio
TSVT
$64K ﹤0.01%
+13,479
New +$60.8K
FULC icon
1513
Fulcrum Therapeutics
FULC
$297M
$61K ﹤0.01%
17,142
-118,079
-87% -$876K
OPTN
1514
DELISTED
OptiNose
OPTN
$61K ﹤0.01%
+6,072
New +$88.5K
STIM icon
1515
Neuronetics
STIM
$166M
$60K ﹤0.01%
78,642
+30,837
+65% +$40.5K
ACET icon
1516
Adicet Bio
ACET
$74.7M
$56K ﹤0.01%
2,451
+1,513
+161% +$33.9K
DRRX
1517
DELISTED
DURECT Corp
DRRX
$56K ﹤0.01%
41,790
-257,715
-86% -$367K
GRRR
1518
Gorilla Technology Group
GRRR
$365M
$55K ﹤0.01%
+12,914
New +$38.6K
IMUX icon
1519
Immunic
IMUX
$195M
$54K ﹤0.01%
3,277
-8,400
-72% -$120K
STKS icon
1520
The ONE Group
STKS
$53M
$54K ﹤0.01%
+14,574
New +$58.6K
BNGO icon
1521
Bionano Genomics
BNGO
$13.3M
$46K ﹤0.01%
+1,674
New +$52.1K
NVTS icon
1522
Navitas Semiconductor
NVTS
$3.63B
$44K ﹤0.01%
+17,860
New +$58K
VFS icon
1523
VinFast Auto
VFS
$7.84B
$44K ﹤0.01%
+11,529
New +$45.6K
WRAP icon
1524
Wrap Technologies
WRAP
$104M
$44K ﹤0.01%
29,656
+10,827
+58% +$17.5K
WHWK
1525
Whitehawk Therapeutics
WHWK
$271M
$43K ﹤0.01%
21,097
-6,392
-23% -$10.3K

Similar funds

GSA Capital Partners's Q3 2024 Portfolio in Review

As of Q3 2024, GSA Capital Partners held 2,115 positions worth $1.32B, down 7.4% from $1.43B the previous quarter. Its ten largest holdings account for 3.7% of the portfolio.

GSA Capital Partners withdrew a net $178M in Q3 2024, closing 578 positions and reducing 531 holdings. Its most notable exit was State Street, an estimated $4.35M position sold in full.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, GSA Capital Partners opened a new position in Idacorp worth $3.23M.

  • GSA Capital Partners's largest Q3 2024 buy was Idacorp: 31,311 shares worth $3.23M.
  • GSA Capital Partners added most to Hudson Pacific Properties in Q3 2024, an estimated $3.7M increase.
  • GSA Capital Partners's biggest Q3 2024 reduction was Fiserv Inc, cutting an estimated $5.58M.
  • GSA Capital Partners fully exited State Street in Q3 2024, selling an estimated $4.35M.
  • GSA Capital Partners's ten largest holdings make up 3.7% of its $1.32B portfolio in Q3 2024.
  • GSA Capital Partners opened 538 new positions and closed 578 in Q3 2024.
  • GSA Capital Partners's portfolio value fell 7.4% quarter-over-quarter to $1.32B.

Based on GSA Capital Partners's 13F filing for Q3 2024, filed 5 Nov 2024.